A 72-year-old man with COPD (FEV1 45% predicted) is already on a long-acting muscarinic antagonist (LAMA) inhaler. He remains symptomatic with mMRC dyspnoea score 3 and has had two moderate exacerbations requiring oral steroids in the last year. What is the most appropriate pharmacological escalation?